The Fund is an actively-managed exchange-traded fund (ETF). The Fund pursues its objective by investing, under normal circumstances, at least 80% of its net assets, including any borrowings for investment purposes, in investment grade fixed-income securities of corporate issuers. Corporate issuers m... The Fund is an actively-managed exchange-traded fund (ETF). The Fund pursues its objective by investing, under normal circumstances, at least 80% of its net assets, including any borrowings for investment purposes, in investment grade fixed-income securities of corporate issuers. Corporate issuers may include corporate or other business entities in which a sovereign or governmental agency or entity may have, indirectly or directly, an interest, including a majority or greater ownership interest. The Funds investment objective is to maximize total return through current income and longterm capital appreciation. Show more
WALTHAM, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced that the Company will attend and present at the 21st...
WALTHAM, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today confirmed that it is scheduled to meet with the U.S. Food and...
WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced financial results for the three-month period ended...
Data confirms results from earlier study WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its study evaluating...
WALTHAM, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
WALTHAM, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
WALTHAM, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.13 | 0.366713681241 | 35.45 | 35.58 | 35.37 | 5081 | 35.47848118 | SP |
4 | -0.7116 | -1.96078431373 | 36.2916 | 36.44 | 35.37 | 8052 | 35.9597218 | SP |
12 | -0.95 | -2.60060224473 | 36.53 | 36.56 | 35.37 | 3015 | 35.98487829 | SP |
26 | 0.0441 | 0.124099853951 | 35.5359 | 37.24 | 35.0184 | 1857 | 36.12599872 | SP |
52 | -0.6622 | -1.82715177335 | 36.2422 | 37.24 | 34.52 | 1131 | 35.93523856 | SP |
156 | 0.38 | 1.07954545455 | 35.2 | 37.24 | 34.52 | 1115 | 35.93420688 | SP |
260 | 0.38 | 1.07954545455 | 35.2 | 37.24 | 34.52 | 1115 | 35.93420688 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.